Summary
In the present study, Mentat, a herbomineral psychotropic preparation, was studied for its pharmacokinetic interaction with the commonly used anti-epileptic drugs, carbamazepine and phenytoin.
The interaction of carbamazepine and phenytoin with Mentat was studied in rabbits. Thirty two rabbits were divided into four groups of eight each. Animals of Group I were treated with carbamazepine (50 mg/kg b.wt. p.o.), Group II were treated with carbamazepine (50 mg/kg b.wt. p.o.) +Mentat (500 mg/kg b.wt. p.o.), Group III were treated with phenytoin (50 mg/kg b.wt.p.o.) and Group IV were treated with phenytoin (50 mg/kg b.wt. p.o.) +Mentat (500 mg/kg b.wt. p.o.) for a period of 8 days. On day 0 and day 8, plasma carbamazepine and phenytoin levels were estimated at different time intervals. A simultaneous treatment with Mentat resulted in a significant increase in plasma AUC of carbamazepine as well as well as phenytoin as compared to carbamazepine or phenytoin alone. Cmax and Tmax of carbamazepine and phenytoin also were evaluated. The results suggest that co-administration of Mentat could improve the effectiveness of anti-epileptic drugs due to the increased bioavailability of the latter. However, this has to be done with critical medical supervision to avoid any toxic reactions and preferably with therapeutic drug monitoring (TDM) which could also help in dose optimization.
Similar content being viewed by others
References
Alan S. Nies, Stephen P. Spielberg (1996): The pharmacological basis of therapeutics. In: Joel G., Hardman, Alfred Goodman, Lee E. Limbird (Eds.) Ninth Edition, Principles of therapeutics. USA: The McGraw-Hill Companies. Inc., 43–62.
Mitra, S.K., Sundaram, R., Venkataranganna, M.V., Gopumadhavan, S. (1999): Pharmacokinetic interaction of Diabecon (D-400) with rifampicin and nifedipine. Eur. J. Drug. Met. Pharmacokin., 24(1): 79–82.
Agarwal Aruna, Manjulatha Dubey, Dubey, G.P. (1991): Effect of Mentat on memory, anxiety scores and neuroticism index in normal subjects in three age groups. Probe, 3: 257–261.
Koti S.T. (1991): Effect of Mentat on school students performance. Probe, 3: 250–252.
Anita Verma, Kulkarni, S.K. (1991a): Nootropic effect of Mentat in Mice. Abstracted in Ind. J. Pharmacol., 23: 8.
Willner P. (1984): The validity of animal models of depression. Psychopharmacol., 83: 1–16.
Battacharya S.K. (1994): Behavioral studies of BR-16A (Mentat) a herbal psychotropic formulation. Ind. J. Expt. Biol., 32(1): 37–43.
Joseph J., Venkataraman B.V., Nagarani, Andrade C. (1994): BR-16A protects against ECS-induced anterograde amnesia. Biol. Psychiatr., 36: 478–489.
Andrade C., Udaya H.B., Suresh Chandra J. (1994): BR-16A restricts development of electroconvulsive shock-induced retrograde amnesia. Biol. Psychiatr., 37: 820–822.
Kulkarni S.K., George B. (1995): Pentylenetetrazole-induced kindling in animals: Protective effect of carbamazepine combination in epilepsy. Clin. Pharmacol. Ther. 18: 733–741.
Moharana D., Moharana S. (1994): A clinical trial of Mentat in patients with varions types of epitephy. Poobe, XXXIII (2): 160–162.
Banerjee S., Mukhejee A. (1994): Mentat (BR-164)-A herbomineral preparation, as an adjuvant to conrentionally used antipieleptic therapy. The Ind. Practit XLVII (II): 929–937.
Hartley H., Lucock M., Gookman J.R., Becker M., Smith I.J., Smithells R.W., Forsythe W.I. (1986): High performance liquid chromatography determination of carbamazepine and carbamazepine 10, 11-epoxide in plasma saliva following solid-phase sample extraction. J. Chromatogr., 380: 347–356.
David L., Thacker, Darrell R. Abemethy, Arthur Raines, David A., Flockhart. (1998): Method for the determination of 5,5-diphenyl barbituric acid and its separation from 1,3-dimethoxymethyl-5,5-diphenybarbituric acid in plasma by HPLC. J. Chromatogr., 710: 149–155.
Hua Liu., Delgado M., Forman L.J., Eggers C.M. and Montoya J.L. (1993): Simultaneous determination of carbamazepine, phenytoin, phenobarbitol, primidone and their principal metabolites by high perfermance liquid chromatography with photodiode-array detection. J. Chromatogr., 616: 105–115.
Hansen J.M., Siersboek-Nielsen K., Skovsted L. (1971): Carbamazepine-induced acceleration of diphenylhydentoin and warfarin metabolism in man. Clin. Pharmacol. Ther. 12: 539–543.
Windorfer A., Sauer W. (1977): Drug interaction during anticonvulsant therapy in childhood: diphenylhydentoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepine, and dipropylacetate. Neuropediatrie., 8: 29–41.
Zielinski J.J., Haidukewych D., Leheta B.J. (1985): Carbamazepine-phenytoin interaction: Elevation of plasma phenytoin concentration due to carbamazepine comedication. Ther. Drug. Monit., 7: 51–53.
Iwahashi K., Miyatake R., Suwaki H., Suwaki H., Hosokawa K., Ichikawa Y. (1995): The drug — drug interaction effects of haloperidol on plasma carbamazepine levels. Clin. Neuropharmacol., 18: 233–236.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tripathi, M., Sundaram, R., Rafiq, M. et al. Pharmacokinetic interactions of mentat with carbamazepine and phenytoin. Eur. J. Drug Metab. Pharacokinet. 25, 223–226 (2000). https://doi.org/10.1007/BF03192318
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03192318